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ABSTRACT
Pancreatic cancer is one of the most lethal types of tumors with
no effective therapy available; is currently the third leading cause
of cancer in developed countries; and is predicted to become the
second deadliest cancer in the United States by 2030. Due to the
marginal benefits of current standard chemotherapy, the iden-
tification of new therapeutic targets is greatly required. Consid-
ering that cAMP pathway is commonly activated in pancreatic
ductal adenocarcinoma (PDAC) and its premalignant lesions, we
aim to investigate the multidrug resistance-associated protein
4 (MRP4)–dependent cAMP extrusion process as a cause of
increased cell proliferation in human PDAC cell lines. Our results
from in silico analysis indicate that MRP4 expression may
influence PDAC patient outcome; thus, high MRP4 levels could
be indicators of poor survival. In addition, we performed in vitro
experiments and identified an association between higher MRP4
expression levels and more undifferentiated and malignant
models of PDAC and cAMP extrusion capacity. We studied the
antiproliferative effect and the overall cAMP response of three
MRP4 inhibitors, probenecid, MK571, and ceefourin-1 in PDAC
in vitro models. Moreover, MRP4-specific silencing in PANC-1
cells reduced cell proliferation (P , 0.05), whereas MRP4
overexpression in BxPC-3 cells significantly incremented
their growth rate in culture (P , 0.05). MRP4 pharmacolog-
ical inhibition or silencing abrogated cell proliferation through the
activation of the cAMP/Epac/Rap1 signaling pathway. Also,
extracellular cAMP reverted the antiproliferative effect of MRP4
blockade. Our data highlight the MRP4-dependent cAMP
extrusion process as a key participant in cell proliferation,
indicating that MRP4 could be an exploitable therapeutic target
for PDAC.
SIGNIFICANCE STATEMENT
ABCC4/MRP4 is themain transporter responsible for cAMPefflux.
In this work, we show that MRP4 expression may influence PDAC
patient outcome and identify an association between higher
MRP4 expression levels and more undifferentiated and malignant
in vitro models of PDAC. Findings prove the involvement of MRP4
in PDAC cell proliferation through a novel extracellular cAMP
mitogenic pathway and further support MRP4 inhibition as a
promising therapeutic strategy for PDAC treatment.
Introduction
The cAMP pathway is one of the most studied signaling
cascades in cellular biology and particularly related to cancer.
It has been demonstrated that aberrant cyclic nucleotide
signaling may play an important role in several types of
neoplasias (Fajardo et al., 2014). Briefly, in this signaling
pathway, the production of cAMP by adenylyl cyclase is
stimulated or inhibited by the activation of G protein–
coupled receptors coupled to a Ga stimulatory subunit or to
a Ga inhibitory subunit, respectively. Once synthesized,
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cAMP acts on its main effectors: protein kinase A (PKA),
exchange proteins activated by cAMP (EPAC), cyclic nucleotide-
gated ion channels, or Popeye domain-containing proteins.
Signal attenuation of this second messenger occurs by its
degradation by phosphodiesterases (PDE), compartmen-
talization, desensitization of G protein–coupled receptors,
and/or extrusion to the extracellular compartment mainly
mediated by the multidrug resistance-associated protein
4 (MRP4)/ABCC4 (Beavo and Brunton, 2002; Sassi et al.,
2009).
Pancreatic ductal adenocarcinoma (PDAC) is one of the
most lethal types of tumors and leading therapeutic chal-
lenges for modern oncology (Rahib et al., 2014). Despite
the recent improvement in survival using FOLFIRINOX
(folinic acid, fluorouracil, irinotecan, and oxaliplatin) or nab-
paclitaxel plus gemcitabine, the 5-year survival rate remains
below 5%–8% (Siegel et al., 2017). Therefore, there is a great
clinical need to identify key molecular and cellular regulators
of PDAC tumor progression and invasion to develop alterna-
tive therapeutic strategies. The carcinogenic process of pan-
creatic cancer accounts for an accumulation of mutations and
genetic lesions in signaling pathways linked to cell prolifera-
tion, motility, and survival. In the last few decades, several
mutations leading to activation of oncogenes, such as KRAS,
GNAS, and BRAF, and inhibition of tumor suppressor genes,
such as p16/CDNKN2A, TP53, SMAD4/DPC4, and BRCA2,
have been identified (Cancer Genome Atlas Research Net-
work, 2017). These mutations are present in the earliest
stages and lowest-grade premalignant lesions of PDAC,
suggesting that they could be essential for the development
and/or progression of the disease, and therefore conceivably
therapeutic targets (Kanda et al., 2012).
Interestingly, frequent activating mutations inGNAS, gene
encoding for the Gas subunit, are not the only alterations
in the canonical cAMP signaling pathway described in PDAC
(Cancer Genome Atlas Research Network, 2017). Recent
studies identified that 59% of the tested human PDAC
samples exhibit an elevated Gas expression compared with
normal tissues, and 72% show an increment in the expression
of phosphorylated substrates of PKA, regardless whether they
haveGNASmutations (Furukawa et al., 2011;Wu et al., 2011;
Kanda et al., 2012; O’Hayre et al., 2013). Also, MRP4 has
shown to be highly expressed in pancreatic cancer tissues, and
its silencing in PDAC cell lines reduces in vitro proliferation
with a cell cycle arrest in G1 phase (Zhang et al., 2012).
However, little is known about the mechanism involved in the
antiproliferative effect of MRP4 inhibition, and there are
limited studies of its potential as a therapeutic target in
cancer. In this regard, it has been recently described that
enhanced intracellular cAMP (i-cAMP) levels upregulate
MRP4 expression through the activation of cAMP/Epac/Rap1
signaling pathway (Bröderdorf et al., 2014; Carozzo et al.,
2015). In recent years, interest in the expression and activity
of MRP4 has been awakened in cancer studies (Yaneff et al.,
2017). Numerous publications describe the antiproliferative
effect of MRP4 inhibition, its upregulation in several tumors,
and its potential as a marker of poor prognosis (Wen et al.,
2015; Yaneff et al., 2017).
Given that: 1) the cAMP pathway is frequently enhanced in
PDAC, 2) intracellular cAMP enhancement is associated with
inhibition of cell proliferation in this type of cancer (Boucher
et al., 2001; Lorenz et al., 2008; Burdyga et al., 2013), and 3)
MRP4 mediates cAMP efflux, we hypothesized that increased
MRP4 expression levels could generate an imbalance between
the ratio of extracellular cAMP (e-cAMP) and i-cAMP that
triggers a global proliferative response in PDAC cells. Thus,
MRP4 inhibition would alter this imbalance and, conse-
quently, impair cell proliferation. In the present work, we
sought to determine the role of the MRP4-dependent cAMP
extrusion process and its involvement in PDAC cell pro-
liferation using human PDAC cell lines with different degrees
of differentiation to propose MRP4 as an exploitable thera-
peutic target for this malignancy.
Materials and Methods
In Silico Analysis of MRP4/ABCC4 Expression among PDAC
Cases
The prognostic value of MRP4/ABCC4 expression in patients with
PDAC was evaluated using the TCGA-PAAD RNAseq pancreatic
dataset obtained from the University of California (Santa Cruz) Xena
resource (https://xena.ucsc.edu). A group of 178 patients with pancre-
atic cancer and follow-up data was classified into low or high
MRP4/ABCC4 mRNA expression levels according to the StepMiner
one-step algorithm (Sahoo et al., 2007). These groups were then
compared based on the recurrence-free survival (Kaplan–Meier curves
and log–rank test) using the Survival R package (Therneau and
Grambsch, 2000).
Cell Lines
Human PDAC cell lines, PANC-1 (CRL-1469), BxPC-3 (CRL-
1687), and HPAF-II (CRL-1997), and human embryonic kidney cell
line, HEK293T (CRL-3216), were obtained from the American Type
Culture Collection and cultured in Dulbecco’s modified Eagle’s
medium (PANC-1, HEK293T) or RPMI 1640 (BxPC-3, HPAF-II)
media (Sigma-Aldrich) supplemented with 10% FBS (Natocor,
Argentina) and 50 mg/ml gentamycin (Sigma-Aldrich) at 37°C in a
humidified 5% CO2 atmosphere. Cells were routinely checked for
mycoplasma contamination using the PlasmoTest (InvivoGen). All
experiments were performed using cells in the exponential growth
phase and when cell viability was above 95%, as determined by
trypan blue (Sigma-Aldrich) assay.
Cell Cycle Synchronization at G0/G1 Phase
Cell cycle synchronization was achieved by serum-starved for
24 hours at 37°C in a humidified 5% CO2 atmosphere, and cells were
relieved into cell cycle by adding 10% FBS.
Western Blotting
A total of 5  105 cells/well was seeded in a 12-well plate in its
respective media supplemented with 10% FBS. After cell attachment,
cells were synchronized and further incubated for 24 hours in fresh
culture media with 10% FBS. In all cases, whole-cell extracts were
obtained using radioimmunoprecipitation assay lysis buffer (Thermo
Fisher Scientific) and resolved by 8% SDS-PAGE loading equal
amounts of protein (20 mg) per lane. Blots were probed concomitantly
as the nitrocellulosemembranes were cut in half to allow two different
primary antibodies to be used. The top half was used to detect MRP4
protein (M4I-10, MA1-35681; 3 mg/ml; Thermo Scientific), and the
bottom half (less than 70 kDa) was used to detect the normalization
protein, b-tubulin (H-300; 1 mg/ml; Abcam), which was used to confirm
equal loading and transfer.
In all cases, reactivity was developed using either anti-rat (sc-2006;
Santa Cruz Biotechnology) or anti-rabbit (PI-1000; Vector Laborato-
ries) antibodies linked to horseradish peroxidase and ECL Western
Blotting Detection Reagent following the manufacturer’s instructions












(AmershamBiosciences). Immunoblots were quantified using Image J
(Schneider et al., 2012). For quantification, the background value of
the scanned gel was subtracted, and the relative abundance was
determined according to MRP4 5 (MRP4)/(b-tubulin). Relative abun-
dance was then normalized respective to the control group.
Quantitative RT-PCR
Cells were seeded in a six-well plate at 5  105 cells/well follow-
ing 24-hour incubation in fresh culturemediawith 10%FBS at 37°C in
a humidified 5% CO2 atmosphere. Total RNA was extracted using
Quick-Zol reagent (Kalium Technologies) and reverse-transcribed
using the High Capacity cDNA Reverse Transcription kit (Applied
Biosystems) following the manufacturer’s instructions. Quantitative
reverse-transcription polymerase chain reaction (qPCR) was per-
formed in triplicate using HOT FIREPol EvaGreen qPCR Mix Plus
(Solis Biodyne) and a Rotor Gene Q detection system (Qiagen); cycling
parameters were as follows: 15 seconds at 94°C, 20 seconds at 60°C,
and 30 seconds at 72°C for 45 cycles. The following primers were used:
hMRP4_FW: 59-GGACAAAGACAACTGGTGTGCC-39, hMRP4_RV:
59-AATGGTTAGCACGGTGCAGTGG-39, b-actin_FW: 59-GGACTTC-
GAGCAAGAGATGG-39, and b-actin_RV: 59-AGCACTGTGTTGGCG-
TACAG-39. The relative MRP4 mRNA quantification was performed
using the comparative DDCt method, with b-actin as the housekeep-
ing gene.
cAMP Radiobinding Protein Assay
In all cases, cells were seeded in 24-well plates at a density of 1 105
cells/well, and, before starting each experiment, culture media was
replaced with phenol red-free media (Sigma-Aldrich) without FBS.
Cells were then exposed to various agents at different concentrations
and time points, as indicated in the corresponding figure legends. No
PDE inhibitors were used during cAMP accumulation assays. Follow-
ing treatment, each well (i-cAMP) and well supernatant (e-cAMP) was
extracted overnight with 95% v/v ethanol. Extracts were then
evaporated, and residues were resuspended in radiobinding protein
(RBP) buffer (50 mM Tris-HCl, 4 mM EDTA, pH 7.4, 0.1% bovine
serum albumin). Blinding was applied to these samples as they were
labeled with consecutive numbers and the corresponding measure-
ments were performed without knowing which sample corresponded
to each number. cAMP content was determined by a competitive
RBP assay for PKA using [3H]-cAMP, as previously described (Davio
et al., 1995). Briefly, titrated PKA was incubated in equilibrium
conditions (2 hours, 4°C) with different samples or cAMP standards
(0.1–90 pmol) in the presence of 2 nM [3H]-cAMP (20.7 Ci/mmol,
NET1161250UC; PerkinElmer) in RBP buffer. The bound fraction
was separated by carbon–dextran precipitation, followed by centri-
fugation (2000g, 15 minutes, 4°C), and Optiphase HiSafe3 scin-
tillation cocktail (PerkinElmer) was added to each supernatant
for counting in a Pharmacia Wallac 1410 counter. Sample cAMP
concentrations were determined by interpolating from the displace-
ment curves obtained from cAMP standards using Prism 6.0 (Graph-
Pad Software). Duplicate samples of at least three independent
experiments were analyzed. For concentration–response assays, we
fit the pooled data from all experiments into a single equation. A
fourth experiment was sometimes needed to properly adjust
concentration–response equations.
Transient Transfections
All transient transfections were carried out as follows: cells at 80%
confluence in a 24-well plate were incubated with 8 ml K2 Multiplier
reagent (Biontex K2 Transfection System) for 2 hours before adding
500 ng either empty vector (control) or coding cDNA constructs with
1 ml K2 transfection reagent in a final volume of 600 ml fresh culture
media. All experiments involving transiently transfected cells were
carried out 24 hours post-transfection, and culturemediawas replaced
with fresh media.
Generation of Stable MRP4-Silenced PANC-1 Cells
Short Hairpin RNA Expression Plasmids. Oligonucleotides
containing two different short hairpin RNA (shRNA) sequences
targeting MRP4 (MRP4-shRNA1 and MRP4-shRNA2) and a scram-
ble shRNA sequence noncomplementary to any human gene were
designed according to the pSUPER.retro.puro Manual (OligoEngine)
and previously validated (Sassi et al., 2008; Copsel et al., 2011).
Oligonucleotides were cloned into the pSUPER.retro.puro vector (Oli-
goEngine); their correct orientation after cloningwas confirmedbyDNA
sequencing using the followingprimer: 59-GGAAGCCTTGGCTTTTG-39
(Macrogen). MRP4-shRNA oligonucleotides contained a MRP4mRNA–
specific region, a hairpin loop region (bold), and a linker sequence for




MRP4-shRNA2 sequence (59-39) sense:GATCCCCGATGGTGCATGTGCAG-
GATTTCAAGAGAATCCTGCACATGCAGCATCTTTTTA; antisense:
AGCTTAAAAAGATGGTGCATGTGCAGGATTCTCTTGAAATCCTG-




Stable PANC-1 Cells Expressing shRNA Targeting MRP4
Retroviruses were generated in HEK293T cells seeded in a 10-cm
plate 1 day prior to calcium phosphate–mediated cotransfection with
a sequence of either pSUPER-MRP4-shRNA or pSUPER-scramble-
shRNA in combination with viral packaging expression plasmids
(Addgene). Viral supernatants were collected 48 hours later and
stored in 280°C after clarification.
Stable expressing pSUPER-MRP4-shRNA1 (PANC-1 MRP4sh1),
pSUPER-MRP4-shRNA2 (PANC-1 MRP4sh2), or pSUPER-scramble-
shRNA (PANC-1 scramble) cells were obtained by transduction in
PANC-1 cells seeded at 1 106/well in a six-well plate 24 hours before
adding 1 ml viral supernatant together with 10 mg/ml polybrene.
Forty-eight hours after infection, clonal selection was carried out in
the presence of 3 mg/ml puromycin (Sigma-Aldrich). Clones were
tested for MRP4 expression by qPCR and Western blot (WB). Specific
clones presenting lower MRP4 expression were chosen for further
experiments and maintained in media containing 1 mg/ml puromycin.
Stable BxPC-3 Cells Overexpressing MRP4
The pcDNA3.1/hygro (2) MRP4 and empty vector were provided by
M. Grube from Institut fur Pharmakologie, Universitat Medizin
Greifswald (Rius et al., 2003). Stable expressing pcDNA3.1/hygro (2)
MRP4 (BxPC-3 MRP4) and empty (BxPC-3 mock) cells were obtained
by transfection of BxPC-3 cells seeded at 1  106/well in a six-well
plate 24 hours before adding the corresponding DNA vector (1 mg)
together with 2 ml K2 Multiplier reagent. Twenty-four hours after
transfection, cells were seeded in the presence of 200 mg/ml hygrom-
ycin B (SelleckChem) for 2 weeks, and clonal selection was carried out
in 96-well plates for another 2 weeks. Finally, clones were tested for
MRP4 expression by qPCR and WB. Both BxPC-3 mock and BxPC-3
MRP4were maintained in media containing 100 mg/ml hygromycin B.
Stable BxPC-3 Cells Overexpressing mTurquoise2-EPAC-
cp173Venus-Venus (Epac-SH187)
Stable expressing pcDNA3.1/Zeo(1)-mTurquoise2-EPAC-cp173Venus-
Venus (Epac-SH187) (BxPC-3 Epac-SH187) and empty (BxPC-3 mock)
cells were obtained by transfection of BxPC-3 cells seeded at 1  106/
well in a six-well plate 24 hours before adding the corresponding
DNA vector (1 mg) together with 2 ml K2 transfecting reagent
(Biontex). Twenty-four hours after transfection, cells were seeded
in the presence of 25 mg/ml zeocine (InvivoGen) for 2 weeks, and












clonal selection was carried out in 96-well plates for another 2 weeks.
Finally, clones were tested for Epac-SH187 by fluorescence spectra
(450–650 nm) measurements in a FlexStation 3 Multi-Mode Micro-
plate Reader (Molecular Devices) with excitation at 430 nm. The
BxPC-3 Epac-SH187 clone with higher fluorescence emission was
chosen for further experiments. Both BxPC-3 mock and BxPC-3
Epac-SH187 were maintained in media containing 25 mg/ml zeocine.
Föster Resonance Energy Transfer Time Course of cAMP
Intracellular Levels with Confocal Microscopy
PANC-1 cells were transfected with mTurquoise2-EPAC-
cp173Venus-Venus (Epac-SH187) (Cell Biophysics & Imaging
Group at Netherlands Cancer Institute) and seeded 4  104 cells/well
in 24-well glass-bottom dishes. After 48 hours, cell imaging was
performed on an inverted LSM 710 (ZEISS) microscope equipped with
an automated stage, an incubation chamber, and the Definite Fo-
cus system. Data acquisition was performed with ZEN Black
2011 software (Carl Zeiss Microscopy). Images were acquired with a
C-Apochromat 40/1.2 water immersion and temperature-corrected
objective lens at 1024  1024 pixels, 16 bits, pixel dwell time 3.15
microseconds, with open pinhole (600mm). The emission spectra of the
fluorescent proteinsmTurquoise2 andVenuswere determined using a
405-nm laser for the excitation and l mode for the detection using a
32-channel QUASAR detector arranged with 9.7-nm bandwidth
channels.
For FRET experiments, cells were illuminated with a 30-mW,
405-nmdiode laser at 2% laser power (550–650 nm gain) and a 405-nm
dichroic mirror; emission was collected at 413- to 723-nmwavelengths
every 15 seconds for 13 minutes. The saturation level was verified for
each image. For the reference spectra and the experiments, phenol
red–free Dulbecco’s modified Eagle’s medium (Sigma-Aldrich) was
used, and imagingwas performed at 37°C and 5%CO2. Approximately
3 minutes after starting the experiment, 25 mM MK571 (Sigma-
Aldrich) or vehicle (0.01% DMSO; Carlo Erba), followed by 0.5 mM
isoproterenol (Tocris) 5 minutes after, was added. For lambda FRET
experiments, the linear unmixing tool of ZENBlack 2011 softwarewas
used to obtain an image for each fluorophore using the reference
spectra. Dead cells fluoresced significantly more than live cells and
were not considered for the analysis. Cell viability was confirmed by
phase–contrast microscopy immediately after the i-cAMP measure-
ment. Image quantification was performed with Fiji software
(Schindelin et al., 2012). After background subtraction, FRET and
donor intensitiesweremeasured for single cells for each time point (six
to eight cells in each treatment, n 5 3). The FRET/donor ratio
intensity was calculated and normalized to basal levels (before
stimulation).
FRET Time Course of cAMP Intracellular Levels with Flex
Station 3
Stable BxPC-3 cells overexpressing mTurquoise2-EPAC-
cp173Venus-Venus (Epac-SH187) or pcDNA3.1/zeo (2) (empty vector)
were seeded in 96-well plates at a density of 1  105 cells/well. Before
starting each experiment, cells were washed with 0.9% NaCl twice,
and 100 ml of this solution was added to each well before placing the
plate in a FlexStation 3 at 37°C. To determine i-cAMP response, we
measured the baseline fluorescence signal detected at 470 (donor) and
510 nm (FRET) emission with excitation at 430 nm. Using the
on-board pipettor, we added 50 ml 3 inhibitor after 40 seconds and
then monitored the signal every 20 seconds for a total of 420 seconds,
both in stable Epac-SH187 and pcDNA3.1/zeo (2) overexpressing cells.
Different concentrations of probenecid, MK571, and ceefourin-1 were
added by automated fluid transfer. After background subtraction
[BxPC-3 pcDNA3.1/zeo (2) treated with each inhibitor concentration],
FRET and donor intensities were calculated in each well for each time
point. The FRET/donor ratio intensities were calculated and normal-
ized to basal levels—before stimulation—(R/R0) for each time point.
Triplicate samples of at least three independent experiments (n 5 3)
were analyzed. For concentration–response assays, we fit the pooled
data from all experiments into a single equation.
Cell Proliferation and Viability Assay
For endpoint experiments, cells growing in exponential phase were
seeded at 1  104 cells/well in a 12-well plate. After synchronization,
cells were incubated for 72 hours in fresh culture media with 10%FBS
in the conditions indicated in each figure legend. For kinetic studies,
cells growing in exponential phase were seeded at 1.5  104 cells/well
in a 12-well plate. After synchronization, cells were incubated for
different time points in fresh culture media with 10% FBS in the
conditions indicated in each figure legend. In all cases, cells were
harvested at the end of the experiment, and the total viable and
nonviable cell number per well were determined by counting in a
hemocytometer chamber after incubation with 0.4% trypan blue.
Blinding was applied during sample preparation and analysis, as
described above for the RBP assays. Triplicate samples of three
independent experiments (n 5 3) were analyzed.
Cell Cycle Analysis
Cells were seeded at 5  105 cells/well in a six-well plate,
synchronized, and incubated for 72 hours in fresh culture media with
10% FBS, as indicated in each figure legend. After treatment, cells
were harvested andwashedwith ice-cold PBS, fixed by addition of 70%
v/v ethanol, and stored at 220°C for 24 hours. Cell suspensions were
washed with ice-cold PBS and incubated with RNase A (100 mg/ml in
PBS; Sigma-Aldrich) at room temperature for 15 minutes. Propidium
iodide (Sigma-Aldrich) was then added to a final concentration of
20 mg/ml and incubated in the dark for 30 minutes. Cell cycle phase
distributions were analyzed by FACScan flow cytometer (Beckton-
Dickinson). Blinding was applied during sample preparation and
analysis, as described above for the RBP assays. Data from duplicates
of three independent experiments (n5 3) were analyzed usingModFit
software (Verity Software House) to determine the fractions of cells in
the G0/G1, S, and G2/M phases from cell cycle distribution.
Statistical Analysis
In all cases, minimum sample size to ensure an adequate statistical
power (.0.95) was determinedwith G*Power 3.1 software (Faul et al.,
2007, 2009) using S.D. values of emerging experimental data as input.
All statistical analyses were performed using Prism 6.0 (GraphPad
Software). All intergroup statistical comparisons were specified before
the experiments started, and all specific intergroup comparisons were
explicitly reported. Experimental results are expressed as mean 6
S.D. of at least three independent experiments (n5 3). Paired samples
comparisonswere used for data analysis of experimentswhere a single
cell line was assessed and unpaired samples comparisons were used in
experiments wheremore than one cell linewas assessed. All t tests are
two-sided with a 5 5%. All analyses of variance are one- or two-way
with post hoc p-adjustments using Bonferroni correction. Values of
P , 0.05 were considered statistically significant.
Results
MRP4 Expression May Influence PDAC Patients’
Outcome. As it has been previously described, higher
MRP4 expression levelswere found in human pancreatic tumor
samples compared with normal tissue, indicating an associa-
tion between MRP4 levels and this type of cancer (Zhang et al.,
2012) To assess the significance of MRP4 protein levels in
PDAC prognosis, we determined whether MRP4 mRNA ex-
pression could be linked to patient overall survival. MRP4 gene
expression profiles from178PDACpatientswere obtained from
TCGA-PAAD dataset and subsequently grouped according to












low or high MRP4 expression levels based on the cutoff value
provided by the StepMiner algorithm (Fig. 1A). As shown in
Fig. 1B, Kaplan–Meier analysis revealed that the subgroup of
patients with high MRP4 expression is associated with a trend
toward shorter recurrence-free survival compared with those
with low expression (P 5 0.15), despite the short follow-up
times of patients available at TCGA-PAAD dataset (median
recurrence-free survival follow-up of 12.8 months). These data
suggest that MRP4 expression may influence PDAC patient
outcome, and that high MRP4 levels could be indicators of poor
survival.
MRP4 Expression in PDAC Cell Lines Is Associated
with cAMP Extrusion. To further understand the role of
MRP4 in PDAC, we evaluated MRP4 expression levels and
functionality in three human PDAC cell lines with different
degrees of differentiation and, therefore, malignancy: HPA-
F-II (well-differentiated), BxPC-3 (moderately-differentiated),
and PANC-1 (poorly-differentiated) cell lines (Iwamura and
Hollingsworth, 2002). Both qPCR and WB studies confirmed
the endogenous expression of MRP4 in the tested cell lines
(Fig. 2A) and showed an association between higher MRP4
expression levels and more undifferentiated and malignant
phenotypes. These findings are consistent with previous
histologic observations of MRP4 expression in human PDAC
samples (Zhang et al., 2012).
Because MRP4 has been described as the main transporter
involved in cAMP extrusion in several cell types (Van Aubel
et al., 2005; Copsel et al., 2011), we evaluated the association
between MRP4 expression levels and this process in PDAC
cells. Treatment with 25 mM forskolin (an adenylyl cyclase
direct activator) induced a rapid increase in i-cAMP levels
during the first 15 minutes of incubation in all cell lines,
followed by a delayed increment in e-cAMP levels (Fig. 2B).We
also characterized the cAMP exclusion process in the pres-
ence of a physiologic stimulus by treating the three cell lines
with the Gas protein-coupled receptor agonists, amthamine
(10 mM) and isoproterenol (10 mM), targeting the histamine-
receptor 2 and the b-adrenergic receptor, respectively. As
expected, both ligands produced an increment in i-cAMP
levels with a concomitant rise in e-cAMP concentrations (P ,
0.05, Supplemental Fig. 1). Given that the maximum i-cAMP
levels (values per 105 cells: HPAF-II 124 6 16 pmol; BxPC-3
65.4 6 7.4 pmol; and PANC-1 43.0 6 3.8 pmol) reached upon
forskolin stimulation varied significantly (P, 0.05) between
the three cell lines tested, we plotted area under the curve
(AUC) values for e-cAMP/AUC of i-cAMP levels from the data
in Fig. 2B, which were obtained from kinetic assays with
forskolin (25 mM, 60 minutes). This ratio is an indicator of
cAMP efflux activity. Figure 2C shows that PANC-1 cells
present the highest AUCe-cAMP/AUCi-cAMP, followed by
BxPC-3 cells and HPAF-II cells, which portray the lowest
value (P , 0.01). To confirm these results, we performed
forskolin concentration–response curves to compare the re-
sponse of each cell line to different i-cAMP levels as in-
dicative of their cAMP efflux activity (Fig. 2D). PANC-1 cells
depict the greatest capacity to exclude cAMP to the extra-
cellular compartment, because they present higher e-cAMP
levels at lower concentrations of i-cAMP, whereas BxPC-3
cells show intermediate capacity, and HPAF-II cells portray
the lowest exclusion capacity for this substrate (Fig. 2D).
Furthermore, when comparing the three cell lines, higher
MRP4 expression levels (Fig. 2A, P , 0.05) were accompa-
nied by higher efflux activity (Fig. 2C, P , 0.01) and vice
versa, thus indicating an association between both aspects.
To confirm MRP4-specific involvement in cAMP extrusion,
we performed studies using MRP4-specific silencing or
overexpression in PDAC cell lines. We established both
MRP4-silenced PANC-1 (Fig. 3A, P , 0.001) and a MRP4-
overexpressing BxPC-3 clone (Fig. 3B, P , 0.01) and
evaluated cAMP response upon forskolin (25 mM, maximum
60 minutes) stimulation. Specific silencing in PANC-1 cells
using two nonoverlapping shRNA sequences (MRP4sh1
and MRP4sh2 cells) led to a decrease in cAMP extrusion
upon forskolin stimulation (P , 0.001) with no significant
changes in i-cAMP levels when compared with control cells
(Fig. 3C). Conversely, the stable MRP4-overexpressing
BxPC-3 clone (BxPC-3 MRP4) led to an increment in
cAMP extrusion upon forskolin stimulation (P , 0.001)
and showed significant lower levels of i-cAMP compared
with the control clone (P , 0.001, BxPC-3 mock, Fig. 3D).
Moreover, basal cAMP extrusion was diminished in PANC-
1 MRP4sh1 (P , 0.05) and augmented in the BxPC-3 MRP4
clone (P , 0.01) compared with their controls over a period
of 1–6 hours without forskolin stimulation, indicating that
MRP4 is the main participant in the cAMP exclusion
process in these cell lines (Fig. 3E). No significant differ-
ences were observed in i-cAMP basal levels between PANC-
1 MRP4sh1 and PANC-1 scramble cells, or between BxPC-3
MRP4 and BxPC-3 mock cells.
The next step was to evaluate the ability of different well-
known MRP4 inhibitors to modulate i-cAMP and e-cAMP
levels after forskolin stimulation. To that end, we performed
concentration–response curves after preincubation (3 min-
utes) with different concentrations of probenecid (a non-
specific anion transporter inhibitor), followed by treatment
with forskolin (33 mM, 30 minutes) in the three PDAC
cell lines (Fig. 4A). Preincubation with probenecid pro-
duced a concentration-dependent decrease in the e-cAMP
levels achieved by forskolin treatment, and concentration–
response curves adjusted a similar apparent IC50 for the
Fig. 1. MRP4 expression may influence patient outcome.
(A) MRP4 gene expression profile from 178 PDAC cancer
patients obtained from TCGA-PAAD RNAseq dataset
(UCSC Xena), classified into two groups according to low
(24/178) or high (48/178)MRP4mRNA levels. (B) Prognostic
value of MRP4 expression in grouped patients. Statistics:
the comparison was based on recurrence-free survival
(Kaplan–Meier curves and log–rank test; P = 0.15).












three cell lines (Fig. 4A). Conversely, i-cAMP levels were not
significantly modified with none of the tested probenecid concen-
trations. We also evaluated the effect of MK571 (a MRP1, 2, and
4 inhibitor) on i-cAMP and e-cAMP levels in response to forskolin
stimuli (Fig. 4B). In the three cell lines, preincubation with
MK571 (25 mM, 5 minutes) led to a great decrease in e-cAMP
levels (P , 0.001), although no significant differences in i-cAMP
levels could be observed 30 minutes after stimuli (Fig. 4B). To
evaluate cAMP levels upon stimulation at a shorter time scale,we
performed kinetic studies in PANC-1 cells after stimulation with
forskolin (25 mM), with or without preincubation with MK571
(25 mM) andmeasured i- and e-cAMP at different time points (0–
5 minutes) by RBP assay (Fig. 4C). Lower e-cAMP levels were
observed in PANC-1 cells pretreated with MK571 starting
3 minutes after forskolin stimulation compared with control cells
(P , 0.01). Also, MK571-treated cells presented higher i-cAMP
levels 5 minutes after forskolin stimulation (P , 0.05). In a
similar approach, we also assessed i-cAMP levels in PANC-1 cells
by FRET assays using Epac-SH187 as a cAMPmolecular sensor in
the presence of isoproterenol (0.5 mM) stimulation, with or
without preincubation with MK571 (25 mM, 3 minutes). Higher
AUC values (0–5minutes, P, 0.05), together with a delay in the
maximum cAMP response to isoproterenol, were observed when
MRP4 was inhibited with MK571 (Fig. 4D). Given that we
observed that the MRP4 inhibitors modified both i- and e-cAMP
levels in short time lapses in the presence of stimulus (forskolin or
isoproterenol), we set out to evaluate their response in basal
conditions. To do so, we measured i-cAMP levels in BxPC-3 cells
by FRETassays using the samemolecular sensor after treatment
with probenecid, MK571, or ceefourin-1 (a novel MRP4-specific
inhibitor) (Cheung et al., 2014) (Fig. 4E). Figure 4E shows
7 minutes i-cAMP kinetics after the addition of 100 mM corre-
sponding inhibitor. To compare potency and efficacy to raise
i-cAMP levels, we performed concentration–response experi-
ments. Probenecid proved to be the most potent and effective
inhibitor [pEC50 (M) 5 3.75 6 0.08], followed by MK571 [pEC50
(M)5 3.2360.10] and ceefourin-1, forwhich potency could not be
calculated properly due to deficiently fit value estimations [pEC50
(M) , 3.83].
Finally, to test the long-term capacity of the inhibi-
tors to alter e-cAMP in absence of stimuli, we used PANC-1
cells, which showed the greatest capacity to exclude cAMP
(Fig. 4F). As expected, we observed a significant reduction in
e-cAMP levels produced by treatment with the three inhib-
itors in basal conditions (P, 0.05). Collectively, these results
confirm that MRP4 inhibition affects temporal i-cAMP and
e-cAMP levels upon stimulation and in basal conditions in
PDAC cell lines.
The Blockage of MRP4 Activity Inhibits PDAC Cell
Proliferation through the Activation of i-cAMP/Epac/Rap1
Signaling Pathway and the Modulation of e-cAMP Levels.
To assess the influence of MRP4 on PDAC cell line growth,
we first evaluated the biologic effect of its pharmacological
inhibition. Treatment with probenecid (0.5 mM), as well as
with MK571 (25 mM), inhibited cell proliferation in the three
cell lines (P , 0.01, Fig. 5A). It is worth noting that none of
the tested concentrations decreased cell viability, thus
discarding any cytotoxic effects that might account for this
observation (data not shown). We further analyzed cell cycle
distribution in PANC-1 cells after MRP4 pharmacological
inhibition. An increase in G0/G1 subpopulation was observed
upon probenecid (P, 0.001) or MK571 (P, 0.05) treatment,
with a concomitant reduction in the percentage of cells in S
phase (Fig. 5B).
To ensure specificity of the antiproliferative response of
MRP4 inhibition, we performed kinetic cell proliferation assays
and cell cycle analysis using the silenced PANC-1 MRP4sh1
clone versus PANC-1 scramble cells and BxPC-3 MRP4 clone
versus BxPC-3 mock cells. Interestingly, silenced PANC-1 cells
exhibited a slower doubling time (Td 5 41.0 6 7.4 hours) than
PANC-1 scramble cells (Td5 33.56 2.9 hours) used as control
(t test, P , 0.05, Fig. 5C). In agreement with previous findings
(Zhang et al., 2012), cell cycle analysis highlighted that
silencing MRP4 increased the G0/G1 population (P , 0.001)
with a concomitant reduction of cells in S phase (P , 0.05)
compared with PANC-1 scramble cells (Fig. 5D). Moreover,
BxPC-3MRP4 cells portrayed a faster doubling time (Td5 12.7
6 2.0 hours) compared with the mock cells (Td 5 22.1 6 6.7
hours) used as control (t test,P, 0.05, Fig. 5E). Unsurprisingly,
when cell cycle was analyzed, an increment in the S (P , 0.01)
Fig. 2. MRP4 expression and cAMP extrusion capacity of PDAC cell lines.
(A) Relative MRP4 mRNA (left) and protein (middle and right) basal
expression levels in PDAC cell lines as determined by qPCR and WB,
respectively. WB results were normalized to b-tubulin as a loading control,
and qPCR results were normalized to b-actin as a housekeeping gene; both
were expressed relative to HPAF-II MRP4 levels. A representative WB
assay of three independent experiments is shown (right). Statistics: one-
way analysis of variance, *P, 0.05; **P, 0.01; ***P, 0.001 vs. HPAF-II
or between data when indicated. (B) Kinetic studies of cAMP production
and extrusion processes. i-cAMP and e-cAMP levels measured by RBP in
PDAC cell lines after treatment with 25 mM forskolin at different time
lapses (0–60 minutes). (C) The ratio of the AUC values for total i-cAMP
and e-cAMP levels from kinetic experiments with forskolin (25 mM,
60 minutes) was plotted for each of the PDAC cell lines. Data are shown
as mean 6 S.D. (n = 3). Statistics: one-way analysis of variance. **P ,
0.01; ***P , 0.001 vs. HPAF-II or between data when indicated. (D)
cAMP extrusion capacity of PDAC cell lines. i-cAMP and e-cAMP levels
were measured by RBP after 30-minute treatment with different
forskolin concentrations (0–333 mM). Results are shown as e-cAMP
vs. i-cAMP levels. (A–D) Data are shown as mean 6 S.D. (n = 3).












and G2/M (P , 0.01) subpopulations was observed in BxPC-3
MRP4 compared with BxPC-3 mock cells (Fig. 5F).
Once proven that MRP4 inhibition or silencing impairs cell
proliferation and cell cycle distribution in PDAC cell lines, we
selected probenecid for further experiments because it showed
to be the most potent and effective inhibitor among those
tested (Fig. 4E) and it has the advantage of being Food and
Drug Administration (FDA) approved, which makes it a good
candidate for drug repositioning (Ahmed et al., 2016).
It has been previously reported that MRP4 silencing
reduces proliferation of PDAC cell lines, but the underlying
mechanism has not yet been described (Zhang et al., 2012).
Because we observed that MRP4 pharmacological inhibi-
tion produced a prompt increment of i-cAMP levels with a
concomitant decrease in e-cAMP levels and that this phe-
nomenon is sustained in time, we evaluated both e- and
i-cAMP levels and how this affected cell proliferation. We
first studied whether the addition of e-cAMP (10 mM) was
able to reverse the antiproliferative effect of MRP4 inhibi-
tion. Remarkably, treatment with cAMP partially reversed
the antiproliferative effect of MRP4 silencing and pharma-
cological inhibition in PDAC cell lines (P, 0.05), although it
did not alter their basal growth rate (Fig. 6A). Accordingly,
exposure to e-cAMP restored the cell cycle distribution of
MRP4-silenced PANC-1 cells, significantly decreasing the
G0/G1 subpopulation (P , 0.05, Fig. 6B). Collectively, these
results reveal a novel role of e-cAMP in pancreatic cancer cell
proliferation. To determine whether the mitogenic effect of
e-cAMP is mediated by any of its extracellular metabolites,
PANC-1 cells were cotreated with probenecid (0.5 mM) and
59AMP (10 mM) or adenosine (10 mM). Interestingly, nei-
ther metabolite could rescue cell proliferation after
MRP4 pharmacological inhibition (Supplemental Fig. 2A).
Similar results were observed when MRP4-silenced PANC-1
cells were treated with 59AMP (10 mM) or adenosine (10 mM)
(Supplemental Fig. 2B). In accordance, inhibition of e-cAMP
degradation by 1,3-dipropyl-8-p-sulfophenylxanthine (59-
nucleotidase inhibitor, 10 mM) or Adenosine 59-[alpha,beta-
methylene]diphosphate (AMPCP, ecto-PDE inhibitor, 10 mM)
did not abrogate its pro-proliferative effect on PANC-1
scramble and MRP4-silenced PANC-1 cells (P , 0.05, Sup-
plemental Fig. 2C). Altogether, these results demonstrate that
e-cAMP can act per se as an autocrine/paracrine growth factor
in PDAC cells and indicate that the MRP4-mediated cAMP
extrusion process provides a mitogenic signal from the
extracellular compartment.
We next studied which of the i-cAMP effectors are involved
in the antiproliferative response triggered by MRP4 inhibi-
tion. Experiments in human coronary artery endothelial cells
have shown that MRP4-specific silencing decreases cell pro-
liferation by activating the cAMP/PKA/cAMP response ele-
ment binding protein pathway (Sassi et al., 2008). However, in
PANC-1 cells, the pharmacological inhibition of PKA with
Fig. 3. MRP4 silencing or overexpression in PDAC cell lines alters the
cAMP extrusion capacity. (A) Relative MRP4 mRNA (left) and protein
(middle and right) basal expression in PANC-1 MRP4-silenced clones
determined by qPCR and WB, respectively. WB results were normalized
to b-tubulin, and qPCR results were normalized to b-actin and both were
expressed relative to PANC-1 scramble MRP4 levels. A representativeWB
assay of three independent experiments is shown (right). Statistics: one-
way analysis of variance vs. PANC-1 scramble. (B) Relative MRP4 mRNA
(left) and protein (middle and right) basal expression in BxPC-3 MRP4-
overexpressing clone determined by qPCR and WB, respectively. WB
results were normalized to b-tubulin as a loading control, and qPCR
results were normalized to b-actin as a housekeeping gene; both were
expressed relative to BxPC-3 mock MRP4 levels. A representative WB
assay of three independent experiments is shown (right). Statistics: t test.
(C and D) Kinetic studies of cAMP production and extrusion processes
afterMRP4 silencing and overexpression. i-cAMP (left) and e-cAMP (right)
levels measured by RBP in PANC-1 MRP4-silenced clones and BxPC-3
MRP4-overexpressing clones after treatment with 25 mM forskolin for
different time lapses (0–60 minutes). AUC values for total i-cAMP and
e-cAMP levels of each condition tested are also shown as a bar plot (right of
curve plot). Statistics: (C) one-way analysis of variance, vs. PANC-1
scramble. (D) t test. (E) Basal cAMP levels after MRP4-specific silencing
(left) or oveexpression (right). i-cAMP and e-cAMP levelsmeasured by RBP
in PANC-1 scramble and PANC-1 MRP4sh1 cells after 60-minute in-
cubation in fresh culture media and in BxPC-3 mock and BxPC-3 MRP4
after 360-minute incubation in fresh culture media. Statistics: t test. (A–E)
Data are shown as mean 6 S.D. (n = 3). *P , 0.05; **P , 0.01; ***P ,
0.001.












KT5720 (1 mM), or its inactivation by expressing a PKA
inhibitor peptide (PKI), did not revert the antiproliferative
effect of MRP4 silencing (Fig. 6C), suggesting the involvement
of another cAMP effector. In addition to PKA, i-cAMP can
activate the Rap1-specific exchange factor Epac. In fact, it has
been proposed that the activation of the Epac/Rap1 cascade
could mediate cAMP-dependent growth inhibition in PDAC
cells (Lorenz et al., 2008). Therefore, we next evaluated
the role of Epac and Rap1 on the antiproliferative effect of
MRP4 inhibition. To attenuate this signaling pathway, we
transiently transfected PANC-1 cells either with the Epac
dominant-negative mutant (N-Epac) or with the Rap1-GAP
construct that accelerates Rap1-GTP hydrolysis favoring its
inactive form. Both strategies abolished the effects of MRP4
pharmacological inhibition (P , 0.05) or silencing (P , 0.05)
on cell proliferation, indicating that MRP4 modulates
Fig. 4. MRP4 inhibitors’ effect on cAMP extrusion in PDAC cell lines. (A) Effect of probenecid (0.00001–0.002M) on i-cAMP and e-cAMP levels in human
PDAC cell lines. i-cAMP and e-cAMP levels were measured by RBP after 3-minute preincubation with probenecid at the indicated concentrations,
followed by treatment with 33mM forskolin for 30minutes. e-cAMP vs. log of probenecid concentration assays were fit to a four-parameter concentration–
response curve. Pool data of all experiments were fit to a single curve. Statistics: one-way analysis of variance. Data are shown as mean 6 S.D. (n = 4).
Statistics: one-way analysis of variance. (B) Endpoint studies of cAMP production and extrusion processes after MRP4 inhibition with MK571. i-cAMP
and e-cAMP levels were measured by RBP after 30-minute treatment with 25 mM forskolin in PDAC cell lines preincubated for 5 minutes with 25 mM
MK571. Data are shown as mean6 S.D. (n = 3). Statistics: t test. (C) Kinetic studies of cAMP production and extrusion processes after MRP4 inhibition
with MK571. i-cAMP (right) and e-cAMP (left) levels measured by RBP in PANC-1 cells preincubated for 5 minutes with 25 mMMK571 after treatment
with 25 mM forskolin for different time lapses (0–5minutes). Statistics: t test. Data are shown as mean6 S.D. (n = 3). (D) Real-time temporal progression
of i-cAMP levels. Time course of FRET changes measured in single PANC-1 cells transiently transfected with the Epac-SH187 cAMP biosensor. Cells
were pretreated for 5 minutes with either 25 mM MK571 or 0.1% DMSO (vehicle control), and, after this treatment, cells were stimulated with 0.5 mM
isoproterenol. Maximum cAMP response was observed 45 seconds after adding isoproterenol and 1.5 minutes in the presence of MK571. Traces are
representative of four independent experiments (mean6 S.D., six to eight cells per treatment, n = 3). AUC values for total cAMP response for each tested
condition are also shown as a scatter plot (right of the curve plot). Statistics: t test. (E) Effect of pharmacological MRP4 inhibition on i-cAMP levels. Time
course of FRET changes in stable BxPC-3 Epac-SH187 cells measured in a Flex Station 3 after the addition of the corresponding inhibitors (100 mM,
7 minutes). Traces are representative of three or four independent experiments (mean 6 S.D.). Concentration–response curves for the three inhibitors
were constructed integrating the AUC of 5-minute R/R0 i-cAMP response for each concentration of all experiments. Pool of AUC values of 5-minute R/R0
i-cAMP response vs. log of concentration of each inhibitor was fit to a four-parameter concentration–response curve. EC50 and top values are reported for
each inhibitor. (F) Basal e-cAMP levels in PANC-1 cells after MRP4 pharmacological inhibition. e-cAMP levels were measured by RBP in PANC-1 cells
treated with 0.5 mM probenecid, 25 mMMK571, or 100 mM ceefourin-1 after 60-minute incubation in fresh culture media. Statistics: one-way analysis of
variance vs. control. Data are shown as mean 6 S.D. (n = 3). (A–F) *P , 0.05; **P , 0.01; ***P , 0.001.












PANC-1 cell growth through the cAMP/Epac/Rap1 pathway
(Fig. 6D).
In conclusion, our findings show that the antiproliferative
effect of MRP4 inhibition in PDAC cells is a consequence of
cAMP augmentation in the intracellular compartment and
a deficiency in the extracellular compartment. The overall
response is the activation of the Epac/Rap1 pathway that
abrogates cell proliferation.
Discussion
The clinical outcome for PDAC patients remains dismal,
and it is clear that there is an urgent need to understand more
about the molecular mechanisms of PDAC pathogenesis and
progression to develop an effective treatment.
Among other participants involved in cancer development,
the role of cAMP signaling pathway in this disease has been
long known (Fajardo et al., 2014); every important compo-
nent of its pathway has been taken into consideration as a
potential cancer drug target (Naviglio et al., 2009; Dou
and Wang, 2010; Savai et al., 2010). However, although
effective, these strategies exhibit toxicity in normal tissues,
probably due to the ubiquitous expression of their molecular
targets (Propper et al., 1999; Schwede et al., 2000). One of
the key participants in the regulation of the cAMP pathway
is MRP4, due to its ability to extrude cyclic nucleotides to
the extracellular space.
Regarding pancreatic cancer, a recent study involving
human pancreatic samples reports that the expression level
of MRP4 is consistently augmented compared with paratumor
tissues, which supports the notion that MRP4 may promote
carcinogenesis (Zhang et al., 2012). Our present study shows
that patients with higher levels of MRP4 expression tend to
have a shorter overall survival than those with lower levels of
MRP4. Thus, a high level of MRP4 expression in PDAC
patients seems to predict a poor prognosis.
In agreement with previous observations (Zhang et al.,
2012), our data show that high MRP4 expression is associated
with low pancreatic cancer cell line differentiation stages.
Likewise, it is well established that cAMP is involved in the
differentiation of many types of cancer cells (Prasad and
Kumar, 1975; Klein and Loizzi, 1977; Prasad et al., 2003;
Moreno et al., 2006; Copsel et al., 2011). In accordance,MRP4
is upregulated in cancer stemlike cells (CSC) (Oevermann
et al., 2009; Warrier et al., 2012), and its inhibition results in
CSC differentiation (Copsel et al., 2014), which may suggest
that undifferentiated cells require active extrusion of cAMP,
or other MRP4 endogenous substrate, to maintain their
pluripotent or immature state.
Unlike other components of the cAMP pathway that are
vastly expressed and widely distributed in the body, MRP4
Fig. 5. Role of MRP4 in cell proliferation. (A) Cell pro-
liferation in response to MRP4 inhibition. Cell proliferation
of PDAC cell lines in the presence of 0.5 mM probenecid or
25 mM MK571 determined by cell count with a hemocytom-
eter chamber after 72-hour incubation in fresh culture
media. Results are expressed relative to the corresponding
control group. Statistics: one-way analysis of variance vs.
control. (B) Cell cycle analysis after MRP4 pharmacological
inhibition. Cell cycle phase distribution of synchronized
PANC-1 cells, treated with 0.5 mM probenecid or 25 mM
MK571 for 72 hours in fresh culture media, was determined
by flow cytometry. Statistics: one-way analysis of variance
vs. control. (C) Cell proliferation of PANC-1 MRP4sh1 and
PANC-1 scramble cells was determined by total cell count-
ing with a hemocytometer chamber. (D) Cell cycle phase
distribution of PANC-1 MRP4sh1 and PANC-1 scramble
cells was determined by flow cytometry in exponentially
growing cells after 72-hour incubation in fresh culture
media. Statistics: t test. (E) Cell proliferation of BxPC-3
MRP4 and BxPC-3 mock was determined by total cell
counting with a hemocytometer chamber. (F) Cell cycle
phase distribution of BxPC-3 MRP4 and BxPC-3 mock
cells was determined by flow cytometry in exponentially
growing cells after 72-hour incubation in fresh culture
media. Statistics: t test. (A–F) *P , 0.05; **P , 0.01;
***P , 0.001 vs. control. Data are shown as mean 6 S.D.
(n = 3). (C and E) Data were adjusted to an exponential
growth equation using Prism 6.0 (GraphPad Software).












is highly expressed in kidneys and prostate, whereas lower
expression levels have been reported in other organs (Borst
et al., 2007; Wen et al., 2015). Some of the physiologic
functions of this transporter were identified in experiments
carried out in Mrp42/2 mice models and include the activa-
tion of platelets and formation of thrombus (Decouture et al.,
2015), testosterone testicular production (Morgan et al.,
2012), and regulation of prostaglandin E metabolite plasma
levels that control the inflammatory pain threshold (Lin
et al., 2008). Nevertheless, these mice did not show major
physiologic alterations (Russel et al., 2008), indicating
that MRP4 inhibition could be a feasible therapeutic ap-
proach. Also, exposition of the knockoutmice to several drugs
highlighted MRP4 role in the excretion of such agents, as
they presented altered cytotoxicity and tissue distribution
compared with wild-type animals (Leggas et al., 2004;
Zamek-Gliszczynski et al., 2006; Takenaka et al., 2007; Liu
et al., 2017). Moreover, several FDA-approved drugs inhibit
MRP4 activity without showing any serious adverse effects
(Yaneff et al., 2017). However, to date, no pharmacological
selective inhibitors of MRP4, with proven in vivo efficacy, are
available. The most widely used MRP4 inhibitors, such as
probenecid and MK571, also have inhibitory activity against
other transporters (Keppler, 2011) and PDE (Xie et al., 2011).
Recently, two selective MRP4 inhibitors have been described
(Cheung et al., 2014), but have not been fully characterized
yet, and their suitability for in vivo studies is still unknown.
In this work, we prove the efficacy of probenecid, MK571, and
ceefourin-1 to inhibit MRP4 activity and, consequently,
enhance i-cAMP and diminish e-cAMP levels.
The FDA has approved the use of probenecid for the
treatment of gout and hyperuricemia four decades ago. This
drug increases excretion of uric acid through urine and, if used
in the recommended doses, has only a few and nonserious side
effects (Ahmed et al., 2016). Notably, oral administration of
probenecid in the average clinically used dose (2 g/day) in
healthy male volunteers causes a mean plasmatic concentra-
tion of 148.6 mg/ml (520.67 mM) (Selen et al., 1982), which is
enough to inhibit PDAC cell proliferation according to our
in vitro studies. Altogether, this points out the potential
clinical relevance of its implementation in the treatment of
PDAC in combination with cytotoxic agents (Fury et al., 2006).
Additionally, because probenecid blocks several MRPs simul-
taneously, its effect could enhance chemotherapeutic drugs,
such as 5-fluorouracil and gemcitabine, which are used to
treat PDAC (Conroy et al., 2011; Von Hoff et al., 2013;
Middleton et al., 2014; Adamska and Falasca, 2018). However,
more studies in this matter, such as preclinical in vivo assays,
should be performed to test the efficacy of the proposed
combined therapy together with the possibility of consequent
Fig. 6. Pharmacological inhibition or silencing of MRP4
inhibits PDAC cell proliferation by activating the cAMP/
Epac/Rap1 signaling pathway. (A) Reversion of the anti-
proliferative effect of MRP4 inhibition and specific silencing
mediated by e-cAMP. Cell proliferation of synchronized
PANC-1, HPAF-II, and BxPC-3 cells preincubated with
0.5 mM probenecid, or PANC-1 scramble and PANC-1
MRP4sh1 cells, was determined by cell count in a hemocy-
tometer chamber after 72-hour treatment with 10 mM
cAMP. Statistics: two-way analysis of variance (to compare
between different cell lines) and t test (to compare treat-
ments from the same cell line); right panel, one-way anal-
ysis of variance vs. control or between data, as indicated. (B)
Effect of e-cAMP addition on cell cycle after MRP4 phar-
macological inhibition. Cell cycle phase distribution of
synchronized PANC-1 cells pretreated with 0.5 mM pro-
benecid was determined by flow cytometry after 72 hours of
incubation with 10 mM cAMP. Statistics: one-way analysis
of variance vs. control or between bars, as indicated. (C)
PKA pathway inhibition effects on cell proliferation in
MRP4-silenced PANC-1 cells. Cell proliferation of PANC-1
scramble and PANC-1 MRP4sh1 cells, either transiently
transfected with pGFP-PKI (codes for a wild-type PKA
inhibitor peptide) and pGFP-PKImut (codes for an inactive
PKA inhibitor peptide) constructs or treated with 1 KT5720
(PKA pharmacological inhibitor), was determined by cell
count in a hemocytometer chamber after 72 hours of
incubation. Statistics: two-way analysis of variance. (D)
Reversion of the antiproliferative effect of MRP4 inhibition
mediated by Epac/Rap1 inhibition. PANC-1 cell prolifera-
tion in response to 0.5 mM probenecid, and PANC-1
scramble and PANC-1 MRP4sh1 cells transiently trans-
fected with either a negative-dominant mutant of Epac
(N-Epac) or a construction that increases Rap1 inactive
form (Rap1-GAP), was monitored by cell count in a hemo-
cytometer chamber 72 hours after incubation. Statistics:
two-way analysis of variance (between different cell lines)
and one-way analysis of variance (within same cell lines);
right panel, one-way analysis of variance vs. control or
between data, as indicated. (A–D) *P , 0.05; **P , 0.01;
***P , 0.001 vs. control or between data when indicated.
Data are shown as mean 6 S.D. (n = 3).












drug–drug interactions. Besides cAMP, MRP4 has the ability
to extrude a wide variety of exogenous and endogenous
substances (Russel et al., 2008; Yaneff et al., 2017). One of
the major problems in PDAC therapy is multidrug resistance,
which not only leads to a reduced efficacy of chemotherapeutic
drugs, but can also favor the survival and expansion of
resistant cancer cells, thus contributing to relapses that
worsen outcomes over time (Choi, 2005; Long et al., 2011;
Murray et al., 2017). Interestingly, it has been described that
drug-resistant cells and CSC from relapsed tumors are
enriched in MRP4, even if the clinically used drugs are not
MRP4 substrates (Tian et al., 2006; Hagmann et al., 2009;
Adema et al., 2014; Moitra, 2015; Adamska and Falasca,
2018). These observations indicate MRP4 inhibition could be
a promising strategy for PDAC treatment, allowing potential
synergetic combinations with currently used chemothera-
peutic drugs by both potentially enhancing their effective-
ness and/or by targeting a resistant cell subpopulation.
Furthermore, the fact thatMRP4 can also export endogenous
prostaglandin E2, a key component in inflammatory path-
ways, may show additional benefits for this therapeutic
strategy, reducing the tumor-associated inflammation,
linked to poor prognosis in pancreatic cancer (Hausmann
et al., 2014).
When analyzing the role of cAMP pathway and its effectors
on physiologic cellular processes such as cell proliferation, we
must bear in mind that both are specific to each cell type
(Stork and Schmitt, 2002; Vitali et al., 2015; Rodríguez et al.,
2017). In this case, for PDAC cell lines we observed that the
inhibition of MRP4 produces an indirect activation of the
cAMP/EPAC/Rap1 pathway that abrogates cell proliferation.
Interestingly, it has previously been reported that EPAC1 is
overexpressed in pancreatic cell lines and tumor samples, and
that activation of the EPAC/Rap1 cascade could mediate
cAMP-dependent growth inhibition in PDAC cells (Lorenz
et al., 2008). Also, consistent with our results, another study
has shown that EPAC inhibition does not alter pancreatic
cancer cell viability nor proliferation in basal conditions
(Almahariq et al., 2013). However, when EPAC/Rap1 pathway
is activated by an enhancement of i-cAMP levels, because of
MRP4 inhibition, both N-Epac and Rap1-GAP transfec-
tions that prevent activation of the pathway can restore cell
proliferation. Moreover, we observed that impairment of
cell proliferation caused by MRP4 inhibition was restored
when cAMP was added to culture medium. Previous studies
have proposed that e-cAMP can modulate a variety of cellular
functions in several tissues, either by acting indirectly,
through its metabolic products, or directly, through a still-
unidentified receptor (Hofer and Lefkimmiatis, 2007). Further
studies are needed to identify this putative cAMP receptor;
thus, its existence would not only expand our understanding
of the cAMP signaling pathway, but could also represent a
newmolecular target for PDAC treatment. Remarkably, four
extracellular cAMP receptors involved in processes such as
chemotaxis, cell migration, and differentiation have been
described in amoeba Dictyostelium discoideum (Schaap,
2011). Recently, a cAMP ABC transporter was also described
in this organism (Miranda et al., 2015). Together, these
findings suggest the existence of a primitive mechanism
linked to e-cAMP signaling in eukaryotic cells. Finally, the
fact that MRP4 inhibition triggers a reduction in e-cAMP
levels could be an invaluable tool for future clinical trials.
Almost 40 years ago, Scavennec et al. (1981) observed that
cAMP concentration in urine was higher in patients with
solid tumors than in healthy volunteers. Therefore, cAMP
levels in urine, or even plasma, could eventually serve as an
efficacy biomarker to assess the patient’s response to MRP4-
targeted therapy.
Altogether, the present study provides direct evidence of
the involvement of MRP4 in cell proliferation of PDAC cell
lines through its involvement in cAMP signaling pathway.
Drug repositioning of an inhibitor such as probenecid or
de novo drug design of a specific inhibitor of cAMP transport
by MRP4 could be appealing strategies to improve PDAC
therapeutics.
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